VC005 / Jiangsu Vcare Pharma, Huadong Medicine - LARVOL DELTA

A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo (clinicaltrials.gov) - P1/2 | N=10 | Not yet recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

New P1/2 trial • Dermatology • Immunology • Vitiligo

Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=84 | Not yet recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

New P1 trial

Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD | Not yet recruiting ➔ Recruiting

Enrollment open • Alopecia • Dermatology • Immunology

Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD | Recruiting ➔ Completed

Trial completion • Renal Disease

Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD | Recruiting ➔ Completed

Trial completion • Hepatology

A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

New P1 trial • Alopecia • Dermatology • Immunology

Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

New P2 trial • Alopecia • Dermatology • Immunology

Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology

A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - P3 | N=360 | Recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD | Not yet recruiting ➔ Recruiting

Enrollment open • Renal Disease

A Food Effect Study of VC005 Tablets in Healthy Adult Subjects. (clinicaltrials.gov) - P1 | N=31 | Completed | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD | Not yet recruiting ➔ Completed | Trial completion date: Oct 2026 ➔ May 2026 | Trial primary completion date: Oct 2026 ➔ Apr 2026

Trial completion • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - P3 | N=360 | Not yet recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

New P1 trial • Hepatology

Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

New P1 trial • Renal Disease

A Food Effect Study of VC005 Tablets in Healthy Adult Subjects. (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - P2 | N=118 | Completed | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD | Recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - P1 | N=11 | Completed | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD | Recruiting ➔ Completed | Trial completion date: Jun 2026 ➔ Feb 2026 | Trial primary completion date: Jun 2026 ➔ Feb 2026

Trial completion • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Jiangsu Vcare PharmaTech Co., Ltd. announced a partnership with Beijing Sun-Novo Pharmaceutical Research…to advance VC005 topical gel (1%), a second‑generation highly selective JAK1 inhibitor, for the treatment of mild to moderate atopic dermatitis (AD) (flcube.com) - "Sun-Novo will receive a revenue share in mainland China and collaborate on Phase III trials and market launch....Next Steps: Phase III trial initiation expected Q2 2026; NDA submission targeted for 2028."

Filing • Licensing / partnership • New P3 trial • Atopic Dermatitis

A multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of VC005 tablets in subjects with non-segmental vitiligo (ChiCTR) - P2 | N=120 | Not yet recruiting | Sponsor: Peking University People's Hospital; Peking University People's Hospital

New P2 trial • Dermatology • Immunology • Vitiligo

Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Vitiligo

Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. (clinicaltrials.gov) - P3 | N=420 | Recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD | Not yet recruiting ➔ Recruiting

Enrollment open • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

New P2 trial • Dermatology • Immunology • Vitiligo